Social Anxiety Disorder (SAD/Social Phobia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Social Anxiety Disorder (SAD/Social Phobia) Clinical Trials Market Report Overview

The social anxiety disorder (SAD/social phobia) trial market research report provides an overview of the social anxiety disorder (SAD/social phobia) trials scenario. The report provides top-line data relating to the clinical trials on social anxiety disorder. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.

Key Regions ·       North America

·       Asia-Pacific

·       Europe

·       Middle East and Africa

·       South and Central America

Key Countries ·       The US

·       Canada

·       United Kingdom

·       Japan

·       Germany

·       France

·       Italy

Key Sponsor Types ·       Company

·       Institution

·       Government

Leading Sponsors ·       GSK plc

·       The Lundbeck Foundation

·       Viatris Inc

·       VistaGen Therapeutics Inc

·       Johnson & Johnson

·       Others

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

SAD Trials Market Segmentation by Regions and Countries

The key regions in the Social Anxiety Disorder (SAD/Social Phobia) trials market are North America, Asia-Pacific, Europe, Middle East and Africa, and South and Central America. North America led with more than 30% of the clinical trials conducted as of August 2023.

In a country-wise analysis, as of August 2023, the US had the highest number of SAD trials, followed by Canada, Russia, Iran China, South Korea, the United Kingdom, Japan, Germany, and Spain.

G7 countries: Among the G7 (United States, United Kingdom, Germany, Canada, Japan, France, and Italy) countries, Canada had the highest proportion of SAD to central nervous system clinical trials as of August 2023. Moreover, out of all the SAD clinical trials conducted in the G7 countries, the majority were in the US.

E7 countries: Among the E7 (China, India, Russia, Turkey, Brazil, Mexico, and Indonesia) countries, Russia had the highest proportion of SAD to Central Nervous System clinical trials as of August 2023. Also, out of all the SAD clinical trials conducted in the E7 countries, the majority were in Russia.

SAD Trials Analysis by Regions, 2023 (%)

SAD Trials Analysis by Regions, 2023 (%)

Buy Full Report to Get More Regional Insights into the SAD Trials Market or,

Download a Free Sample Report

SAD Trials Market Segmentation by Sponsor Types

The key sponsor types in the SAD trials market are company, institution, and the government. In August 2023, the company sponsor type dominated the SAD trials market share, followed by the institution.

SAD Trials Market Analysis by Sponsor Types, 2023 (%)

SAD Trials Market Analysis by Sponsor Types, 2023 (%)

Buy Full Report to Get More Sponsor Type Insights into the SAD Trials Market or,

Download a Free Sample Report

SAD Trials Market - Competitive Landscape

The leading sponsors in the SAD trials market are GSK plc, the Lundbeck Foundation, Viatris Inc, VistaGen Therapeutics Inc, Johnson & Johnson, and others. In 2023, GSK plc has conducted the highest number of SAD trials.

SAD Trials Market Analysis by Sponsors, 2023 (%)

SAD Trials Market Analysis by Sponsors, 2023 (%)

Buy Full Report to Know More About the Leading Players in the SAD Trials Market or,

Download a Free Sample Report

Scope

  • The report provides a snapshot of the global clinical trials landscape.
  • The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
  • The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
  • The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
  • The report provides enrollment trends for the past five years.
  • The report provides the latest news for the past three months.

Reasons to Buy

  • Assists in formulating key business strategies concerning investment.
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
  • Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
  • Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
  • Facilitates clinical trial assessment of the indication on a global, regional, and country level.

GSK plc
The Lundbeck Foundation
Viatris Inc
Johnson & Johnson
VistaGen Therapeutics Inc
Novartis AG
Pfizer Inc
AbbVie Inc
AstraZeneca Plc
Aurobindo Pharma Ltd

Table of Contents

Table of Contents 2

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Social Anxiety Disorder (SAD/Social Phobia) to Central Nervous System Clinical Trials 16

Clinical Trials by Phase in G7 Countries 18

Clinical Trials in G7 Countries by Trial Status 19

Clinical Trials by E7 Countries: Proportion of Social Anxiety Disorder (SAD/Social Phobia) to Central Nervous System Clinical Trials 21

Clinical Trials by Phase in E7 Countries 23

Clinical Trials in E7 Countries by Trial Status 24

Clinical Trials by Phase 26

In Progress Trials by Phase 27

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 31

Clinical Trials by Sponsor Type 32

Prominent Sponsors 33

Top Companies Participating in Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials 35

Prominent Drugs 37

Clinical Trial Profile Snapshots 39

Appendix 212

Abbreviations 212

Definitions 212

Research Methodology 213

Secondary Research 213

About GlobalData 214

Contact Us 214

Source 215

Table

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials by Region, 2023* 7

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2023* 9

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2023* 10

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2023* 11

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2023* 12

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, North America, Top Countries, 2023* 13

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2023* 14

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Central and South America, Top Countries, 2023* 15

Proportion of Social Anxiety Disorder (SAD/Social Phobia) to Central Nervous System Clinical Trials, G7 Countries (%), 2023* 17

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2023* 18

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2023* 20

Proportion of Social Anxiety Disorder (SAD/Social Phobia) to Central Nervous System Clinical Trials, E7 Countries (%), 2023* 22

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2023* 23

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2023* 25

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials by Phase, 2023* 26

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials In Progress by Phase 2023* 27

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials by Trial Status, 2023* 29

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, by End Point Status, 2023* 30

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2018-2022 31

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2023* 32

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, Key Sponsors, 2023* 34

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2023* 36

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2023* 38

Figures

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials by Region (%), 2023* 7

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2023* 8

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2023* 10

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2023* 11

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2023* 12

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, North America, Top Countries (%), 2023* 13

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2023* 14

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2023* 15

Proportion of Social Anxiety Disorder (SAD/Social Phobia) to Central Nervous System Clinical Trials, G7 Countries (%), 2023* 16

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2023* 18

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2023* 19

Proportion of Social Anxiety Disorder (SAD/Social Phobia) to Central Nervous System Clinical Trials, E7 Countries (%), 2023* 21

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2023* 23

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2023* 24

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials by Phase (%), 2023* 26

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2023* 27

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics, Global, Clinical Trials by Trial Status, 2023* 28

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, by End Point Status, 2023* 30

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2018-2022 31

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2023* 32

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, Key Sponsors, 2023* 33

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2023* 35

Social Anxiety Disorder (SAD/Social Phobia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2023* 37

GlobalData Methodology 223

Frequently asked questions

Social Anxiety Disorder (SAD/Social Phobia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Social Anxiety Disorder (SAD/Social Phobia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Social Anxiety Disorder (SAD/Social Phobia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update in real time.

  • Access a live Social Anxiety Disorder (SAD/Social Phobia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.